文献速递淋巴瘤白血病

Ublituximab联合Umbralisib治疗复发/难治性B细胞非霍奇金淋巴瘤及慢性淋巴细胞白血病

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2019-01-01

这项1/1b期研究评估了PI3K-δ抑制剂Umbralisib联合抗CD20单抗Ublituximab(U2方案)在复发/难治性CLL或NHL患者中的安全性和初步疗效。采用3+3剂量递增设计,未达到最大耐受剂量,仅观察到1例剂量限制性毒性。所有患者总缓解率46%,完全缓解率17%,中位缓解持续时间20个月(95%CI 11.3-未达到),安全性与单药Umbralisib相比无新信号。

要点

  • U2方案在复发/难治性B细胞恶性肿瘤中耐受性良好,3级及以上腹泻、肺炎、肝毒性发生率分别为8%、8%、4%。
  • 所有患者总缓解率46%,完全缓解率17%,中位缓解持续时间20个月(95%CI 11.3-未达到)。
  • CLL和NHL队列均未达到最大耐受剂量,仅1例剂量限制性毒性,因不良事件停药率13%。

核心结论

  • U2方案(Ublituximab联合Umbralisib)在复发/难治性CLL和NHL中耐受性良好,未观察到超越单药Umbralisib的新安全信号。
  • 初步疗效令人鼓舞,总缓解率46%,完全缓解率17%,中位缓解持续时间20个月(95%CI 11.3-未达到),值得进一步研究。

研究设计与样本

  • 1/1b期研究,采用3+3剂量递增设计确定最大耐受剂量。
  • 纳入复发/难治性CLL或NHL患者,Ublituximab静脉给药(NHL 900 mg;CLL 600或900 mg)共12周期。
  • Umbralisib口服每日一次,剂量递增阶段800或1200 mg(初始制剂)或400-1200 mg(微粉化制剂),1b期阶段800-1200 mg,直至疾病进展、毒性或退出研究。

主要发现

  • CLL和NHL队列均未达到最大耐受剂量,仅观察到1例剂量限制性毒性。
  • 3级及以上腹泻发生率8%,肺炎8%,肝毒性4%。
  • 因不良事件治疗中断率13%,Umbralisib剂量减少率15%。
  • 所有患者总缓解率46%,完全缓解率17%。
  • 中位缓解持续时间20个月(95%置信区间11.3-未达到)。

关键数值与推荐

  • 3级及以上腹泻发生率8%,肺炎8%,肝毒性4%。
  • 因不良事件治疗中断率13%,Umbralisib剂量减少率15%。
  • 总缓解率46%,完全缓解率17%。
  • 中位缓解持续时间20个月(95%置信区间11.3-未达到)。

临床怎么用

  • U2方案可作为复发/难治性B细胞非霍奇金淋巴瘤和慢性淋巴细胞白血病的一种耐受性良好的治疗选择。
  • 治疗期间需监测腹泻、肺炎和肝毒性等不良事件,必要时调整Umbralisib剂量或中断治疗。

局限性

  • 本研究为1/1b期研究,样本量未在摘要中报告,疗效数据为初步结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting both CD20 and phosphatidylinositol 3-kinase (PI3K), a protein that is critically involved in B-cell maturation, could be an efficacious strategy for treating B-cell malignancies. The safety of the next-generation compounds umbralisib, a PI3K-δ inhibitor, plus ublituximab, an anti-CD20 monoclonal antibody (combination referred to as U2), was evaluated in patients with chronic lymphocytic lymphoma (CLL) or non-Hodgkin lymphoma (NHL) in this phase 1/1b study. Phase 1 dose escalation was performed with a 3 + 3 design to establish the maximum tolerated dose. In this portion, ublituximab was given intravenously (NHL, 900 mg; CLL, 600 or 900 mg) for 12 cycles. Umbralisib was given orally once daily at 800 or 1200 mg (initial formulation) or 400 to 1200 mg (micronized formulation) in the phase 1 dose escalation portion, and at 800 to 1200 mg in the phase 1b portion until progression, toxicity, or study removal. The maximum tolerated dose was not reached in either the CLL or NHL cohort, and only 1 dose-limiting toxicity was observed. U2 had low instances of grade 3 or higher diarrhea (8%), pneumonia (8%), or hepatic toxicity (4%). Treatment discontinuation due to adverse events occurred in 13% of patients, and umbralisib dose reductions occurred in 15% of patients. The overall response rate for all patients was 46% with 17% complete responses. The median duration of response was 20 months (95% confidence interval, 11.3-not reached). U2 was well tolerated, and no new safety signals were observed over single-agent umbralisib. Preliminary efficacy with this combination is promising and warrants further investigation. This study was registered at www.clinicaltrials.gov as #NCT02006485.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lunning M, Vose J, Nastoupil L, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019. PMID: 31558467. doi:10.1182/blood.2019002118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。